Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sun Yat-sen Univ. BLM compound 21
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
01
Overview
Sun Yat-sen Univ. BLM compound 21: sourced facts only. name: "After evaluating their BLM inhibitory activity, the SAR was discussed, leading to identifying compound 21 as a promising BLM inhibitor." [PMID:36459756]; target: "After evaluating their BLM inhibitory activity, the SAR was discussed, leading to identifying compound 21 as a promising BLM inhibitor." [PMID:36459756]; developer: "School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou, 510006, China." [PMID:36459756]; stage: "21 exhibited the potent BLM-dependent cytotoxicity against the CRC cells but weak against normal cells." [PMID:36459756]
02
Targets
BLM (BLM helicase)
Beyond the preview
Go deeper on Sun Yat-sen Univ. BLM compound 21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sun Yat-sen Univ. BLM compound 21.